TY - JOUR
T1 - A three-dimensional (3D) organotypic microfluidic model for glioma stem cells – Vascular interactions
AU - Truong, Danh
AU - Fiorelli, Roberto
AU - Barrientos, Eric S.
AU - Melendez, Ernesto Luna
AU - Sanai, Nader
AU - Mehta, Shwetal
AU - Nikkhah, Mehdi
N1 - Funding Information:
Patient-derived glioma cells were provided by the Biobank Core Facility @ St. Joseph's Hospital and Barrow Neurological Institute. The Biobank is funded by the Arizona Biomedical Research Commission and the Barrow Neurological Foundation. Additionally, DT and MN would like to acknowledge 2017–2018 Achievement Rewards for College Scientists Foundation Scholarship, and the 2016–2018 International Foundation for Ethical Research Fellowship. Funding sources for SM includes R01NS088648 and for NS includes R01NS082745. Zachary Camacho is acknowledged for his assistance with microfluidic device preparation. Lastly, CD-31 antibody was purchased from the Developmental Studies Hybridoma Bank, deposited to the DSHB by Wayner, E.A./Vercellotti, G., and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.
Funding Information:
Patient-derived glioma cells were provided by the Biobank Core Facility @ St. Joseph's Hospital and Barrow Neurological Institute. The Biobank is funded by the Arizona Biomedical Research Commission and the Barrow Neurological Foundation . Additionally, DT and MN would like to acknowledge 2017–2018 Achievement Rewards for College Scientists Foundation Scholarship, and the 2016–2018 International Foundation for Ethical Research Fellowship. Funding sources for SM includes R01NS088648 and for NS includes R01NS082745 . Zachary Camacho is acknowledged for his assistance with microfluidic device preparation. Lastly, CD-31 antibody was purchased from the Developmental Studies Hybridoma Bank, deposited to the DSHB by Wayner, E.A./Vercellotti, G., and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242.
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2019/4
Y1 - 2019/4
N2 - Glioblastoma (GBM) is one of the deadliest forms of cancer. Despite many treatment options, prognosis of GBM remains dismal with a 5-year survival rate of 4.7%. Even then, tumors often recur after treatment. Tumor recurrence is hypothesized to be driven by glioma stem cell (GSC) populations which are highly tumorigenic, invasive, and resistant to several forms of therapy. GSCs are often concentrated around the tumor vasculature, referred to as the vascular niche, which are known to provide microenvironmental cues to maintain GSC stemness, promote invasion, and resistance to therapies. In this work, we developed a 3D organotypic microfluidic platform, integrated with hydrogel-based biomaterials, to mimic the GSC vascular niche and study the influence of endothelial cells (ECs) on patient-derived GSC behavior and identify signaling cues that mediate their invasion and phenotype. The established microvascular network enhanced GSC migration within a 3D hydrogel, promoted invasive morphology as well as maintained GSC proliferation rates and phenotype (Nestin, SOX2, CD44). Notably, we compared migration behavior to in vivo mice model and found similar invasive morphology suggesting that our microfluidic system could represent a physiologically relevant in vivo microenvironment. Moreover, we confirmed that CXCL12-CXCR4 signaling is involved in promoting GSC invasion in a 3D vascular microenvironment by utilizing a CXCR4 antagonist (AMD3100), while also demonstrating the effectiveness of the microfluidic as a drug screening assay. Our model presents a potential ex vivo platform for studying the interplay of GSCs with its surrounding microenvironment as well as development of future therapeutic strategies tailored toward disrupting key molecular pathways involved in GSC regulatory mechanisms.
AB - Glioblastoma (GBM) is one of the deadliest forms of cancer. Despite many treatment options, prognosis of GBM remains dismal with a 5-year survival rate of 4.7%. Even then, tumors often recur after treatment. Tumor recurrence is hypothesized to be driven by glioma stem cell (GSC) populations which are highly tumorigenic, invasive, and resistant to several forms of therapy. GSCs are often concentrated around the tumor vasculature, referred to as the vascular niche, which are known to provide microenvironmental cues to maintain GSC stemness, promote invasion, and resistance to therapies. In this work, we developed a 3D organotypic microfluidic platform, integrated with hydrogel-based biomaterials, to mimic the GSC vascular niche and study the influence of endothelial cells (ECs) on patient-derived GSC behavior and identify signaling cues that mediate their invasion and phenotype. The established microvascular network enhanced GSC migration within a 3D hydrogel, promoted invasive morphology as well as maintained GSC proliferation rates and phenotype (Nestin, SOX2, CD44). Notably, we compared migration behavior to in vivo mice model and found similar invasive morphology suggesting that our microfluidic system could represent a physiologically relevant in vivo microenvironment. Moreover, we confirmed that CXCL12-CXCR4 signaling is involved in promoting GSC invasion in a 3D vascular microenvironment by utilizing a CXCR4 antagonist (AMD3100), while also demonstrating the effectiveness of the microfluidic as a drug screening assay. Our model presents a potential ex vivo platform for studying the interplay of GSCs with its surrounding microenvironment as well as development of future therapeutic strategies tailored toward disrupting key molecular pathways involved in GSC regulatory mechanisms.
UR - http://www.scopus.com/inward/record.url?scp=85062290587&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062290587&partnerID=8YFLogxK
U2 - 10.1016/j.biomaterials.2018.07.048
DO - 10.1016/j.biomaterials.2018.07.048
M3 - Article
C2 - 30098794
AN - SCOPUS:85062290587
SN - 0142-9612
VL - 198
SP - 63
EP - 77
JO - Biomaterials
JF - Biomaterials
ER -